Nanovesicles derived from coprococcus sp. bacteria, and use thereof

A technology of Coprolococcus and vesicles, which is applied in the field of bacterial nanovesicles and its applications, and can solve the problems of unreported Coprococcus bacteria secreting vesicles, unreported diagnosis and treatment of refractory diseases, etc.

Pending Publication Date: 2020-11-03
MD HEALTHCARE INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there have been no reports of extracellular secretion of vesicles by Coprolococcus bacteria, especially the use of vesicles for the diagnosis and treatment of intractable diseases such as cancer or cardio-cerebral diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanovesicles derived from coprococcus sp. bacteria, and use thereof
  • Nanovesicles derived from coprococcus sp. bacteria, and use thereof
  • Nanovesicles derived from coprococcus sp. bacteria, and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1. Analysis of In vivo Absorption, Distribution and Excretion Patterns of Gut Bacteria and Bacteria-Derived Vesicles

[0084] To assess whether gut bacteria and bacterial-derived vesicles are absorbed systemically through the gastrointestinal tract, the following experiments were performed. First, a dose of 50 μg of each of the fluorescently labeled intestinal bacteria and the vesicles derived from intestinal bacteria was administered to the stomach of the mouse through the gastrointestinal tract, and at 0 minutes, 5 minutes, 3 hours, and 6 hours and measure fluorescence after 12 hours. As a result of observing the whole image of the mouse, as Figure 1A As shown, bacteria were not taken up systemically, but vesicles derived from bacteria were absorbed systemically at 5 minutes after administration, and strong fluorescence was observed in the bladder at 3 hours after administration, thus showing that the vesicles were excreted to the urinary tract. Furthermo...

Embodiment 2

[0086] Example 2. Metagenomic analysis of bacterial-derived vesicles in clinical samples

[0087]After the blood was first placed in a 10 ml tube and the suspension was settled by centrifugation (3,500 xg, 10 min, 4°C), only the supernatant was transferred to a new 10 ml tube. After removing bacteria and impurities using a 0.22-μm filter, transfer them to a Centriprep tube (centrifugal filter 50kD) and centrifuge at 1,500×g and 4°C for 15 minutes, discard the material smaller than 50kD, and the residue Concentrate to 10ml. After bacteria and impurities were removed again using a 0.22-μm filter, supernatant was discarded and aggregated pellets were dissolved by performing ultracentrifugation at 150,000×g and 4°C for 3 hours using a 90Ti type rotor in normal saline (PBS).

[0088] 100 μl of vesicles isolated by the method described above were boiled at 100 °C to extract internal DNA from lipids, and then cooled on ice for 5 min. Then, in order to remove the residual suspens...

Embodiment 3

[0092] Example 3. Metagenomic analysis of bacterial-derived vesicles in the blood of breast cancer patients

[0093] Genes were extracted from the vesicles present in the blood of 96 breast cancer patients and 192 normal individuals (both groups were matched in age and sex), and after using the method in Example 2 to perform metagenomic analysis on the blood, the source The distribution of vesicles in Coprolococcus bacteria was assessed. As a result, it was confirmed that vesicles derived from bacteria of the genus Faecalis were significantly reduced in blood from breast cancer patients compared with blood from normal individuals (see Table 2 and Table 2). figure 2 ).

[0094] [Table 2]

[0095]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
absorbanceaaaaaaaaaa
Login to view more

Abstract

The present invention relates to vesicles derived from Coprococcus sp. bacteria, and a use thereof. The present inventors experimentally confirmed that: compared to those of a normal person, the vesicles are significantly reduced in clinical samples from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation; and when the vesiclesisolated from a strain are administered, the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from Escherichia coli, is notably inhibited. Thus, the vesicles derived from Coprococcus sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation; and a composition for preventing, treating or improving gastritis, stomach cancer, colitis, colorectal cancer, breast cancer, ovarian cancer,bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or inflammatory diseases.

Description

technical field [0001] The present invention relates to nanovesicles derived from bacteria of the genus Coprococcus and uses thereof, and more particularly, to diagnosis of breast cancer, ovarian cancer, bladder cancer, Methods for myocardial infarction, cardiomyopathy, atrial fibrillation and similar diseases, and methods for preventing, alleviating or treating gastritis, gastric cancer, colitis, colon cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, Compositions of cardiomyopathy, atrial fibrillation or inflammatory disease. Background technique [0002] Since the early 2000s, acute infectious diseases, which in the past were considered epidemics, have become less important, while chronic inflammatory diseases accompanied by immune dysfunction due to discord between humans and microbiomes have transformed disease pattern, becoming a major disease that determines the quality of life and human longevity. As intractable chronic diseases in the 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/689C12Q1/6851A23L33/135A61K35/74A61P35/00A61P37/00
CPCY02A50/30C12Q1/689C12Q1/6851A23L33/135A61K35/74A61P35/00A61P37/00C12Q2600/112A23V2002/00A23V2200/308
Inventor 金润根
Owner MD HEALTHCARE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap